工具类服务
编辑部专用服务
作者专用服务
FOLFIRI方案成功治疗伴有肾功能不全的转移性结肠癌1例报道
目的 探讨FOLFIRI方案治疗伴有肾功能不全的转移性结肠癌的疗效和安全性.方法 患者为55岁男性,结肠癌术后11个月出现肝脏、肺脏、腰椎多发转移,伴有明显的肾功能不全.第1周期FOLRIRI方案具体剂量为:CPT-11 100mg/m2·d IVgtt 90min D1 q21d、CF 200mg/m2·d IVgtt 2h D1,2 q21d、5-Fu 400mg/m2·d IV Bolus D1,2 q21d、600mg/m2·d CIV 22h D1,2 q21d.第2至6周期CPT-11剂量调整为150mg/m2·d,CF、5-Fu剂量保持不变.治疗过程中严密监测肾功能,化疗前及第4周期化疗结束后2周分别行PET/CT检查.结果 PET/CT检查提示肝脏、肺部及腰椎转移病灶完全消失,达到完全缓解,肿瘤指标CEA由治疗前的21.26μg/L恢复到正常,治疗过程中未发现明显肾功能损害.结论 FOLFIRI方案治疗伴有肾功能不全的转移性结肠癌具有较好的疗效和安全性.
作者单位：
解放军第101医院血液肿瘤科,无锡,214044
同济大学附属同济医院肿瘤科
年，卷(期)：
机标分类号：
在线出版日期：
本文读者也读过
相关检索词
万方数据知识服务平台--国家科技支撑计划资助项目（编号：2006BAH03B01）(C)北京万方数据股份有限公司
万方数据电子出版社工具类服务
编辑部专用服务
作者专用服务
FOLFOX4与FOLFIRI方案治疗晚期结直肠癌近期疗效观察
目的 观察FOLFOX4方案与FOLFIRI方案治疗晚期结直肠癌的近期疗效及不良反应.方法 FOLFOX4组24例,用奥沙利铂(L-OHP)联合5-Fu/CF;FOLFIRI组22例,用伊立替康(CPT-11)联合5-Fu/CF.均为每2周重复1次.2次为1周期,化疗1疗程(2周期)后观察疗效及不良反应.结果FOLFOX4组完全缓解0例,部分缓解9例,有效率37.5%,稳定9例,进展6例,不良反应中末梢神经毒性较明显;FOLFIRI组完全缓解0例,部分缓解8例,有效率36.4%,稳定9例,进展5例,不良反应中迟发性腹泻、胆碱能神经综合征较明显.结论 两种方案均有较好的近期疗效,可获得相似的结果,差异无统计学意义,不良反应可以控制,为治疗晚期结直肠癌的有效方案.
作者单位：
金湖,金湖县中医院肿瘤科,江苏,211600
年，卷(期)：
机标分类号：
在线出版日期：
本文读者也读过
相关检索词
万方数据知识服务平台--国家科技支撑计划资助项目（编号：2006BAH03B01）(C)北京万方数据股份有限公司
万方数据电子出版社Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: Study design and preliminary safety results - ScienceDirect
Export JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page., February 2001, Pages 35-40Author links open overlay panelShow moreAbstractThe aim of this randomized open-label study was to compare a bimonthly with a monthly regimen of 5-fluorouracil (5-FU) and leucovorin for the adjuvant treatment of colon and high-rectum adenocarcinoma. The bimonthly regimen was administered for 2 consecutive days every 14 days as d,L-leucovorin 200 mg/m2 or L-leucovorin 100 mg/m2 as a 2-hour infusion followed by 5-FU bolus of 400 mg/m2 and a 600 mg/m2 5-FU 22-hour continuous infusion (LV5FU2). In the monthly regimen, d,L-leucovorin 200 mg/m2 or L-leucovorin 100 mg/m2 15-minute infusion followed by a 400 mg/m2 15 minute 5-FU bolus was administered for 5 consecutive days every 28 days (FUFOL). Nine hundred five patients with recently resected stage B2 or C colon or high-rectum adenocarcinoma (inferior pole of the tumor subperitoneal) were recruited into the study. Patients were randomized in a 2 × 2 factorial design to receive either LV5FU2 or FUFOL for 24 or 36 weeks. Characteristics of the patients in the two different treatment groups were similar at baseline. Compliance was good. Mean 5-FU dose intensities were 930 mg/ m2/wk and 463 mg/m2/wk for LV5FU2 and FUFOL, respectively. The incidence of maximal grade III–IV toxicities for LVSFU2 and FUFOL was neutropenia 6% and 16% (P & .001), diarrhea 4% and 10% (P & .001), and mucositis 2% and 7% (P & .001), respectively. Maximum grade III–IV toxicities in the LV5FU2 treatment group were significantly lower than in the FUFOL group (10% v 26%; P & .001). Although patients in the LV5FU2 group received twice the dose of 5-FU compared with those in the FUFOL group, LV5FU2 was shown to be less toxic. Efficacy data will be available in 2001.Check if you have access through your login credentials or your institution.ororRecommended articlesCiting articles (0)First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin
(Folfox 4) Versus 5-FU/LV (de Gramont Regimen)
First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin
(Folfox 4) Versus 5-FU/LV (de Gramont Regimen)
Click on image to view larger version.
Anticancer Research}